NASDAQ$BIOX

Bioceres Crop Solutions Corp · Q3 2026 earnings

Q3 2026 earnings · · Before market open · Investor relations

Briefing

Bioceres fiscal Q3 2026: revenue falls 23% to $39.4M as Seeds transition and Crop Protection softness weigh

Bioceres Crop Solutions reported fiscal third quarter 2026 results for the three months ended March 31, 2026. Total revenue from continuing operations was $39.4 million, down 23% from $51.1 million in Q3 2025, reflecting softer Crop Protection demand, competitive pressures, and the ongoing transition in Seeds toward a more asset-light model. Crop Protection revenue fell 18% to $24.6 million, Seed and Integrated Products revenue declined 71% to $3.2 million, while Crop Nutrition grew 15% to $11.6 million on microbeaded fertilizer demand. Gross profit was $12.7 million with a 32% margin versus 35% a year ago, impacted by product mix and a non-recurring inoculants obsolescence adjustment. The company reported a net loss of $10.0 million and adjusted EBITDA of $(0.6) million, compared with net income of $2.3 million and adjusted EBITDA of $9.1 million in Q3 2025. SG&A fell 16% to $16.1 million as cost-management initiatives continued amid Pro Farm litigation and liability-management efforts.

  • Total revenue fell 23% to $39.4M; Crop Protection down 18% to $24.6M and Seeds down 71% to $3.2M, partly offset by Crop Nutrition up 15% to $11.6M.
  • Gross profit was $12.7M with 32% margin, down from $18.1M and 35% in Q3 2025, including a non-recurring inoculants obsolescence charge.
  • Net loss was $10.0M versus net income of $2.3M; adjusted EBITDA was $(0.6)M compared with $9.1M a year ago.
  • SG&A declined 16% to $16.1M through organizational streamlining and cost management across continuing operations.
  • Management is advancing liability-management initiatives and a strategic review while navigating Pro Farm foreclosure litigation.

Headline financials

Total Revenue

$39.4M

Previous: $59.6M-33.9%
SG&A expenses

$16.1M

No prior period
Adjusted EBITDA

-$600K

No prior period
Consolidated gross margin

32.0%

Previous: 39.0%-17.9%
Net Income

-$10M

Previous: -$1.3M-666.9%

Revenue & EPS history

Bioceres · Revenue · Quarterly

$39.4M

Q3 2026-33.9%vs Q3 2025
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Revenue by segment

Bioceres · $39.4M total across 3 segments · Q3 2026

  • Crop protection
    $24.6M-42.3%
  • Crop nutrition
    $11.6M+49.2%
  • Seed and integrated products
    $3.2M-68.5%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2026

Historical avgQ3 2026

-0.9%

Avg return

Earnings day

-0.0%

Avg return

5 days after

-3.9%

Avg return

30 days after

41%

12 / 29 earnings

Positive

+12.6%

Q3 2023

Best reaction

-14.4%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-5.6%-20.1%-20.7%
Q2 2026-9.2%-12.8%-16.0%
Q3 2025-5.2%-0.4%-2.4%
Q4 2024-14.4%-15.2%-26.2%
Q3 2024-7.0%-10.8%-16.2%
Q2 2024+4.0%+3.1%+1.5%
Q1 2024+6.7%+13.6%+28.0%
Q4 2023-2.3%-0.4%-4.1%
Q3 2023+12.6%+20.3%+22.5%
Q2 2023-8.4%-2.4%-6.8%
Q1 2023+5.5%+1.9%-12.7%
Q4 2022-2.9%-2.9%-10.3%
Q3 2022+5.4%+12.8%+9.7%
Q2 2022+1.8%+1.4%+19.1%
Q1 2022+8.2%+15.9%+9.0%
Q4 2021-6.5%-8.2%-2.2%
Q3 2021+3.0%+5.6%-5.3%
Q2 2021-1.9%-1.7%-7.5%
Q1 2021-0.2%-0.7%-7.2%
Q4 2020+4.8%+7.0%+17.9%
Q3 2020-6.6%-1.9%-4.0%
Q2 2020+4.7%+13.5%-12.5%
Q1 2020-5.5%-0.7%-7.7%
Q4 2019+0.0%-7.4%-6.6%
Q3 2019-8.7%-11.1%-7.2%
Q2 2019+0.2%+0.2%-47.4%
Q1 2019+0.0%+0.0%+2.6%
Q4 2018+0.2%+0.0%+0.2%
Q3 2018+0.0%+0.7%+0.5%
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro